Skip to main content

Table 3 Univariate and multivariate analysis results of overall survival rates

From: Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system

Variables

Overall Survival Rates

Univariate Analysis

Multivariate Analysis

n

2-year

3-year

p-value

HR (95%CI)

p-value

Stage

IA

193

79

70

0.0348

-

0.0693

IB + IIA

90

65

50

 

1.484 (0.968–2.242)

 

Histology

Adenocarcinoma

184

79

69

0.0689

-

0.5293

SCC

79

69

52

 

1.151 (0.737–1.772)

 

Gender

Female

69

86

83

0.0016

-

0.0015

Male

214

71

58

 

2.393 (1.380–4.418)

 

Location

Upper and Middle

165

76

65

0.925

-

0.9900

Lower

118

73

62

 

0.997 (0.660–1.489)

 

BED (10) IC (Gy)

≥ 90

264

75

65

0.4428

-

0.6830

< 90

19

68

56

 

1.145 (0.570–2.083)

 

Margins from GTV to PTV (mm)

≥ 10

156

72

63

0.3268

-

0.6307

< 10

123

77

64

 

0.904 (0.596–1.355)

 
  1. BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, OS overall survival, PTV planning target volume, SCC squamous cell carcinoma